The effects of sacubitril-valsartan tablets on the expressions of NT-proBNP,cTnⅠ and cardiac function in patients with chronic cardiac insufficiency
10.12173/j.issn.1008-049X.202311096
- VernacularTitle:沙库巴曲缬沙坦片对慢性心功能不全患者血浆NT-proBNP、cTnⅠ表达及心功能的影响
- Author:
Qiu-Shi WANG
1
;
Xiao-Ran LI
;
Yao YAO
Author Information
1. 首都医科大学附属北京友谊医院心内科(北京 100050)
- Keywords:
Sacubitril-valsartan tablets;
Chronic cardiac insufficiency;
N terminal pro B type natriuretic peptide;
Troponin Ⅰ;
Cardiac function
- From:
China Pharmacist
2023;26(11):298-303
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effects of sacubitril-valsartan tablets on the expressions of N terminal pro B type natriuretic peptide(NT-proBNP),troponin Ⅰ(cTnⅠ)and cardiac function in patients with chronic cardiac insufficiency.Methods Patients with chronic cardiac insufficiency who were diagnosed and treated in Beijing Friendship Hospital of Capital Medical University from November 2021 to December 2022 were selected as the study subjects,and were divided into the study group(sacubitril-valsartan tablets)and the control group(valsartan capsules)according to the random number table method.The total effective rate,cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD),left ventricular end-diastolic diameter(LEVDD)],plasma NT-proBNP,cTnⅠ,soluble growth stimulation expression gene 2 protein(sST2),angiotensin(AngⅡ)and the incidence of adverse reactions were observed in the two groups.Results A total of 100 patients with cardiac insufficiency were included in the study,with 50 in the study group and 50 in the control group.After treatment,the total effective rate of the study group was higher than that of the control group(P＜0.05).The LVEF in the study group was significantly higher than that in the control group,while the LVESD,LEVDD were significantly lower than those in the control group(P＜0.05).After treatment,the plasma of NT-proBNP,cTnⅠ,AngⅡ,and sST2 in two groups had statistical difference(P＜0.05)and the difference in the above indicators before and after treatment in two groups were statistically siginficant(P＜0.05).The differences in adverse reactions between two groups were not statistically significant(P＞0.05).Conclusion The treatment of chronic heart failure patients with sacubitril-valsartan tablets can improve heart function,prognosis,and safety.
